S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.95 (+1.83%)
AAPL   143.11 (+4.01%)
MSFT   260.86 (+3.29%)
FB   196.36 (+1.46%)
GOOGL   2,234.39 (+2.58%)
AMZN   2,152.65 (+0.04%)
TSLA   674.40 (+1.58%)
NVDA   169.59 (+1.59%)
BABA   87.52 (+0.84%)
NIO   15.93 (-3.10%)
AMD   95.00 (+1.60%)
CGC   5.20 (-5.80%)
MU   69.59 (+1.00%)
T   20.75 (+1.72%)
GE   75.44 (+0.25%)
F   12.84 (+2.72%)
DIS   105.85 (+3.35%)
AMC   11.62 (-3.41%)
PFE   52.86 (+0.74%)
PYPL   81.19 (+0.81%)
NFLX   187.98 (+0.87%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.95 (+1.83%)
AAPL   143.11 (+4.01%)
MSFT   260.86 (+3.29%)
FB   196.36 (+1.46%)
GOOGL   2,234.39 (+2.58%)
AMZN   2,152.65 (+0.04%)
TSLA   674.40 (+1.58%)
NVDA   169.59 (+1.59%)
BABA   87.52 (+0.84%)
NIO   15.93 (-3.10%)
AMD   95.00 (+1.60%)
CGC   5.20 (-5.80%)
MU   69.59 (+1.00%)
T   20.75 (+1.72%)
GE   75.44 (+0.25%)
F   12.84 (+2.72%)
DIS   105.85 (+3.35%)
AMC   11.62 (-3.41%)
PFE   52.86 (+0.74%)
PYPL   81.19 (+0.81%)
NFLX   187.98 (+0.87%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.95 (+1.83%)
AAPL   143.11 (+4.01%)
MSFT   260.86 (+3.29%)
FB   196.36 (+1.46%)
GOOGL   2,234.39 (+2.58%)
AMZN   2,152.65 (+0.04%)
TSLA   674.40 (+1.58%)
NVDA   169.59 (+1.59%)
BABA   87.52 (+0.84%)
NIO   15.93 (-3.10%)
AMD   95.00 (+1.60%)
CGC   5.20 (-5.80%)
MU   69.59 (+1.00%)
T   20.75 (+1.72%)
GE   75.44 (+0.25%)
F   12.84 (+2.72%)
DIS   105.85 (+3.35%)
AMC   11.62 (-3.41%)
PFE   52.86 (+0.74%)
PYPL   81.19 (+0.81%)
NFLX   187.98 (+0.87%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.95 (+1.83%)
AAPL   143.11 (+4.01%)
MSFT   260.86 (+3.29%)
FB   196.36 (+1.46%)
GOOGL   2,234.39 (+2.58%)
AMZN   2,152.65 (+0.04%)
TSLA   674.40 (+1.58%)
NVDA   169.59 (+1.59%)
BABA   87.52 (+0.84%)
NIO   15.93 (-3.10%)
AMD   95.00 (+1.60%)
CGC   5.20 (-5.80%)
MU   69.59 (+1.00%)
T   20.75 (+1.72%)
GE   75.44 (+0.25%)
F   12.84 (+2.72%)
DIS   105.85 (+3.35%)
AMC   11.62 (-3.41%)
PFE   52.86 (+0.74%)
PYPL   81.19 (+0.81%)
NFLX   187.98 (+0.87%)
NASDAQ:BLPH

Bellerophon Therapeutics (BLPH) Stock Forecast, Price & News

$0.93
+0.01 (+1.09%)
(As of 05/23/2022 03:59 PM ET)
Add
Compare
Today's Range
$0.93
$0.93
50-Day Range
$0.85
$2.43
52-Week Range
$0.67
$5.95
Volume
4 shs
Average Volume
56,939 shs
Market Capitalization
$8.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.17
30 days | 90 days | 365 days | Advanced Chart
Receive BLPH News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellerophon Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Bellerophon Therapeutics logo

About Bellerophon Therapeutics

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLPH
Fax
N/A
Employees
21
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
$1.69 per share

Profitability

Net Income
$-17.76 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
7,502,000
Market Cap
$8.88 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/11/2022
Today
5/23/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.24 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -













Bellerophon Therapeutics (NASDAQ:BLPH) Frequently Asked Questions

Is Bellerophon Therapeutics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Bellerophon Therapeutics stock.
View analyst ratings for Bellerophon Therapeutics
or view top-rated stocks.

When is Bellerophon Therapeutics' next earnings date?

Bellerophon Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Bellerophon Therapeutics
.

How were Bellerophon Therapeutics' earnings last quarter?

Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) released its quarterly earnings results on Wednesday, May, 11th. The biotechnology company reported ($0.59) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by $0.04.
View Bellerophon Therapeutics' earnings history
.

When did Bellerophon Therapeutics' stock split? How did Bellerophon Therapeutics' stock split work?

Bellerophon Therapeutics shares reverse split on the morning of Monday, February 10th 2020. The 1-15 reverse split was announced on Friday, February 7th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 7th 2020. An investor that had 100 shares of Bellerophon Therapeutics stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for BLPH?

2 equities research analysts have issued 1 year price targets for Bellerophon Therapeutics' stock. Their forecasts range from $19.00 to $19.00. On average, they expect Bellerophon Therapeutics' share price to reach $19.00 in the next twelve months. This suggests a possible upside of 1,943.0% from the stock's current price.
View analysts' price targets for Bellerophon Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Bellerophon Therapeutics' key executives?
Bellerophon Therapeutics' management team includes the following people:
  • Mr. Peter Fernandes M. Pharm, Principal Exec. Officer and Chief Regulatory, Safety & Quality Officer (Age 67, Pay $476.35k)
  • Mr. Nicholas Laccona, Controller, Principal Financial & Accounting Officer and Sec. (Age 33)
  • Dr. Parag Suresh Shah, VP of Bus. Operations (Age 45)
  • Dr. Edwin L. Parsley, Acting Chief Medical Officer (Age 61)
What other stocks do shareholders of Bellerophon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Corbus Pharmaceuticals (CRBP), Novavax (NVAX), Pfizer (PFE), Verastem (VSTM), Gilead Sciences (GILD), OPKO Health (OPK), SCYNEXIS (SCYX) and Dynavax Technologies (DVAX).

When did Bellerophon Therapeutics IPO?

(BLPH) raised $60 million in an initial public offering on Friday, February 13th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Leerink Partners and Cowen and Company acted as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers.

What is Bellerophon Therapeutics' stock symbol?

Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH."

Who are Bellerophon Therapeutics' major shareholders?

Bellerophon Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Jane Street Group LLC (0.39%). Company insiders that own Bellerophon Therapeutics stock include New Mountain Investments Ii, L and Wassim Fares.
View institutional ownership trends for Bellerophon Therapeutics
.

Which institutional investors are selling Bellerophon Therapeutics stock?

BLPH stock was sold by a variety of institutional investors in the last quarter, including Jane Street Group LLC.
View insider buying and selling activity for Bellerophon Therapeutics
or view top insider-selling stocks.

How do I buy shares of Bellerophon Therapeutics?

Shares of BLPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bellerophon Therapeutics' stock price today?

One share of BLPH stock can currently be purchased for approximately $0.93.

How much money does Bellerophon Therapeutics make?

Bellerophon Therapeutics has a market capitalization of $8.88 million. The biotechnology company earns $-17.76 million in net income (profit) each year or ($1.89) on an earnings per share basis.

How many employees does Bellerophon Therapeutics have?

Bellerophon Therapeutics employs 21 workers across the globe.

What is Bellerophon Therapeutics' official website?

The official website for Bellerophon Therapeutics is www.bellerophon.com.

How can I contact Bellerophon Therapeutics?

Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The biotechnology company can be reached via phone at (908) 574-4770 or via email at [email protected].

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.